US FDA finalises "changes being effected" labelling rule
This article was originally published in Scrip
The US FDAhas finalised a controversial rule clarifying the types of drug and biological labelling changes that can be made through a "changes being effected" (CBE) supplement without prior agency approval. The timing of the final measure, just seven months after the proposed rule was released, seems to be aimed at bolstering the government and industry in a closely watched drug labelling pre-emption case that will be argued before the Supreme Court on November 3rd.
You may also be interested in...
Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.
AstraZeneca and Merck seek to add a pancreatic cancer indication for olaparib, while Merck has hopes of broadening pembrolizumab’s use in bladder cancer; two-day Oncologic Drugs Advisory Committee meeting also will include reviews of Celgene’s luspatercept in myelodysplastic syndromes-related anemia and Epizyme’s tazemetostat for epithelioid sarcoma.
Clinicians and sponsors want the US FDA to open up antibacterial labeling to include more data on efficacy against resistant pathogens and in other body sites, but regulatory restrictions may require a workaround in the form of rapid, peer-to-peer communications about the data on new products.